These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 22843938)

  • 1. Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.
    Todenhöfer T; Hennenlotter J; Feyerabend S; Aufderklamm S; Mischinger J; Kühs U; Gerber V; Fetisch J; Schilling D; Hauch S; Stenzl A; Schwentner C
    Anticancer Res; 2012 Aug; 32(8):3507-13. PubMed ID: 22843938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
    Čapoun O; Mikulová V; Jančíková M; Honová H; Kološtová K; Sobotka R; Michael P; Zima T; Hanuš T; Soukup V
    Anticancer Res; 2016 Apr; 36(4):2019-26. PubMed ID: 27069196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
    BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
    Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
    Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.
    Todenhöfer T; Hennenlotter J; Dorner N; Kühs U; Aufderklamm S; Rausch S; Bier S; Mischinger J; Schellbach D; Hauch S; Feniuk N; Bedke J; Gakis G; Stenzl A; Schwentner C
    J Cancer Res Clin Oncol; 2016 May; 142(5):1013-20. PubMed ID: 26910601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
    Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
    Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
    Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
    Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
    Strijbos MH; Gratama JW; Schmitz PI; Rao C; Onstenk W; Doyle GV; Miller MC; de Wit R; Terstappen LW; Sleijfer S
    Eur J Cancer; 2010 Jul; 46(11):2027-35. PubMed ID: 20399640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
    Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
    Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive prostate-specific antigen circulating cells detected by reverse transcriptase-polymerase chain reaction does not imply the presence of prostatic micrometastases.
    Thiounn N; Saporta F; Flam TA; Pages F; Zerbib M; Vieillefond A; Martin E; Debré B; Chevillard S
    Urology; 1997 Aug; 50(2):245-50. PubMed ID: 9255296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
    Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
    Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.
    Shaffer DR; Leversha MA; Danila DC; Lin O; Gonzalez-Espinoza R; Gu B; Anand A; Smith K; Maslak P; Doyle GV; Terstappen LW; Lilja H; Heller G; Fleisher M; Scher HI
    Clin Cancer Res; 2007 Apr; 13(7):2023-9. PubMed ID: 17404082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative chemosensitivity of circulating human prostate cancer cells and primary cancer cells.
    Menen R; Zhao M; Zhang L; Hassanein MK; Bobek V; Kolostova K; Bouvet M; Hoffman RM
    Anticancer Res; 2012 Jul; 32(7):2881-4. PubMed ID: 22753751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
    Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2.
    Kawakami M; Okaneya T; Furihata K; Nishizawa O; Katsuyama T
    Cancer Res; 1997 Oct; 57(19):4167-70. PubMed ID: 9331068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
    Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E
    BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
    Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
    Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.